Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal polysaccharide vaccine, groups A, C, Y and W135
- Development stage
- Unknown
- Lead developer
- Walvax Biotechnology
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Yuxi Walvax MPV ACYW is a quadrivalent meningococcal polysaccharide vaccine developed by Walvax Biotechnology. It is indicated for the prevention of invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, Y, and W-135. The vaccine contains purified capsular polysaccharides from each of the four serogroups and is administered via intramuscular injection. It is primarily used in pediatric and adult populations to provide protection against meningitis and septicaemia. In clinical trials, such as the Phase IV study NCT05441410, it has been evaluated for immunogenicity and safety in children aged 2 to 10 years, often compared against conjugate vaccines like Menactra to demonstrate its clinical profile in real-world settings.
- Brand names
- Yuxi Walvax MPV ACYWMPV ACYW
- Other names
- Meningococcal Polysaccharide Vaccine Groups A, C, Y and W135
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal polysaccharide vaccine, groups A, C, Y and W135.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal polysaccharide vaccine, groups A, C, Y and W135.